Biotechs choose their law firm early, often at formation, and then keep them for years. That single fact should reshape how legal and IP firms think about business development, because it means the client you win at seed stage may still be your client when they are running a Phase 3.
The relationship starts before the company is worth anything
A biotech needs counsel from almost the first day: incorporation, founder agreements, the first patent filings, the seed round. At that moment, the company has little money and enormous stakes, since the patent decisions made then will define the protection of their core assets for two decades.
Firms that write off emerging companies as too small miss the point entirely. The client is not the company today. The client is the company in five years, and the relationship is being decided now, when they are choosing whoever they can find and afford.
What they are actually assessing
- Do you genuinely understand the science? An attorney who cannot follow the biology cannot draft claims that protect it. Founders can tell within one conversation, and technical depth is the single most valuable thing an IP firm can demonstrate.
- Have you done this for companies like ours? Emerging biotech legal work has its own rhythms, and founders want someone who has been through it before.
- Who actually does the work? A partner who pitches and an associate who executes is a familiar and resented pattern.
- Can we afford you? Fee structure matters enormously to a company managing runway, and firms that engage sensibly with that reality win relationships that later become very valuable.
Referrals dominate, but only if you are findable
Most biotech legal work comes through referral: investors recommend firms, founders ask other founders, boards have opinions. This makes your standing in the startup and investor ecosystem the core of your business development.
But referral and discoverability are not alternatives, they reinforce each other. A founder given a name will look you up. A founder given no name will search. In both cases, what they find, or fail to find, determines whether the conversation happens.
The compounding asset
Every emerging biotech you help well becomes a reference, a referral source, and potentially a major client. Firms that build a reputation as the people who understand emerging biotech, and who are easy to find when a new company goes looking, build a client base that grows as their clients do.
Be the company they find
The biotech that will be your biggest client in five years is choosing counsel right now, with almost no money and enormous stakes. Be the firm they find.
Get a featured listing and dedicated landing page, $5,000/year
Or start with a featured profile, $3,000/year
Both carry a 90-day guarantee: if your listing does not generate measurable referral traffic, we extend it by a quarter at no cost. Browse the legal and IP directory to see exactly where your company would sit, and read how biotech buyers actually choose vendors for the wider picture.
Frequently asked questions
How do biotechs choose a law or IP firm?
Usually early, often at formation, and then they keep the firm for years. They assess whether the attorneys genuinely understand the science (critical for drafting patent claims that actually protect the asset), whether the firm has worked with similar companies, who will actually do the work, and whether the fee structure fits a company managing runway.
Why should law firms target early-stage biotechs?
Because the client is not the company today, it is the company in five years. Biotechs choose counsel at formation and keep them through growth, so the relationship won at seed stage may still be in place at Phase 3. Firms that write off emerging companies as too small miss the point of how these relationships form.
How do biotech law firms win clients?
Largely through referrals from investors, founders and boards, which makes standing in the startup ecosystem central. But referral and discoverability reinforce each other: a founder given a name will look you up, and a founder given no name will search. What they find, or fail to find, determines whether the conversation happens.
